Clinical Scorecard: EULAR Updates Behçet’s Syndrome Recommendations

At a Glance

Key Highlights

• Earlier use of biologic DMARDs (bDMARDs), especially monoclonal anti–tumor necrosis factor alpha antibodies, is recommended for eye, vascular, and nervous system involvement to prevent organ damage.
• Colchicine remains first-line for mucocutaneous and joint involvement, with escalation to apremilast or TNF inhibitors if refractory or intolerant.
• High-dose glucocorticoids plus infliximab recommended for arterial aneurysms; immunosuppressives and biologics prioritized over systemic glucocorticoid monotherapy.

Guideline-Based Recommendations

Diagnosis

• Assess organ involvement regularly including endoscopy for gastrointestinal disease.
• Use clinical and angiographic criteria to monitor uveitis remission.

Management

• Use colchicine as first-line for mucocutaneous lesions and acute arthritis.
• Consider apremilast or TNF inhibitors for colchicine-refractory mucocutaneous disease.
• Administer immunosuppressives and biologics (preferably infliximab) for Behçet’s uveitis and severe vascular or nervous system involvement.
• Avoid chronic systemic glucocorticoid monotherapy; use topical glucocorticoids for oral/genital ulcers.
• Treat arterial aneurysms with high-dose glucocorticoids plus infliximab; cyclophosphamide as alternative.
• Use glucocorticoids and immunosuppressives promptly for venous thrombosis; add anticoagulants cautiously.
• Manage gastrointestinal involvement based on endoscopy; use 5-aminosalicylic acid or azathioprine for mild/moderate disease, biologics for severe/refractory cases.
• For active parenchymal nervous system disease, initiate high-dose glucocorticoids and immunosuppressives, preferably infliximab, with slow tapering.

Monitoring & Follow-up

• Ongoing assessment of organ involvement to guide treatment adjustments.
• Monitor clinical and angiographic remission in uveitis.
• Evaluate treatment response and adverse events, especially when using biologics.

Risks

• Avoid chronic systemic glucocorticoid monotherapy due to adverse effects.
• Consider bleeding risk when adding anticoagulants in venous thrombosis.
• Be aware of limited randomized trial data and heterogeneity in evidence.

Patient & Prescribing Data

Patients with various organ involvement in Behçet’s syndrome, including refractory cases

Randomized trials support colchicine as first-line for mucocutaneous and joint disease; adalimumab shows superior mucocutaneous remission and uveitis control compared to cyclosporine-A; infliximab preferred over cyclophosphamide for vascular involvement with higher remission and fewer adverse events.

Clinical Best Practices

• Implement individualized, multidisciplinary care with patient education and shared decision-making.
• Prioritize early biologic therapy in eye, vascular, and nervous system involvement to prevent irreversible damage.
• Use a step-up approach for mucocutaneous and joint disease starting with colchicine.
• Avoid systemic glucocorticoid monotherapy; use in combination with immunosuppressives or biologics when indicated.
• Base gastrointestinal management on endoscopic findings and disease severity.
• Regularly monitor disease activity and treatment response to adjust therapy accordingly.

References

• Annals of the Rheumatic Diseases - EULAR Behçet’s Syndrome Recommendations Update